Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AM-Pharma
Biotech
Ambrose inks $181M deal for former Pfizer target AM-Pharma
Ambrose Healthcare has bought AM-Pharma for up to 161 million euros, inking a cut-price deal for a biotech once courted by Pfizer.
Nick Paul Taylor
Oct 20, 2026 2:00am
Exscientia fires CEO—Chutes & Ladders
Feb 16, 2024 9:30am
Takeda welcomes new oncology chief from CRISPR—Chutes & Ladders
Feb 9, 2024 9:30am
AM-Pharma cuts staff, CEO leaves as lead asset redirected
Sep 26, 2023 10:39am
AM-Pharma, once a Pfizer takeover target, flunks phase 3 trial
Oct 20, 2022 7:30am
Kyowa Kirin licenses AM-Pharma phase 3 asset for up to $289M
Sep 8, 2021 9:28am
